Avalo Therapeutics (NASDAQ:AVTX) Shares Down 8.2% – Time to Sell?

Avalo Therapeutics, Inc. (NASDAQ:AVTX)’s share price traded down 8.2% during trading on Wednesday . The stock traded as low as $18.24 and last traded at $18.0880. 461,480 shares changed hands during trading, a decline of 59% from the average session volume of 1,137,270 shares. The stock had previously closed at $19.71.

Analyst Ratings Changes

Several brokerages have issued reports on AVTX. Bank of America assumed coverage on shares of Avalo Therapeutics in a research report on Friday, June 12th. They issued a “buy” rating and a $35.00 price objective for the company. Wedbush lowered their price target on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Wall Street Zen raised shares of Avalo Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. Citizens Jmp decreased their price objective on shares of Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating for the company in a research report on Thursday, May 14th. Finally, Leerink Partners started coverage on Avalo Therapeutics in a research note on Monday, July 6th. They set an “outperform” rating and a $38.00 target price for the company. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $45.10.

Avalo Therapeutics Stock Down 8.2%

The firm has a market capitalization of $970.17 million, a price-to-earnings ratio of -4.14 and a beta of 0.78. The stock has a 50 day moving average of $19.14 and a 200 day moving average of $17.02.

Avalo Therapeutics (NASDAQ:AVTX) last released its earnings results on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). Analysts predict that Avalo Therapeutics, Inc. will post -2.59 earnings per share for the current year.

Insiders Place Their Bets

In other Avalo Therapeutics news, insider Mittie Doyle sold 1,450 shares of the stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00. Following the sale, the insider directly owned 51,776 shares of the company’s stock, valued at approximately $931,968. This represents a 2.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 3,129 shares of company stock worth $59,680 in the last three months. 4.46% of the stock is owned by insiders.

Institutional Trading of Avalo Therapeutics

Several hedge funds have recently made changes to their positions in AVTX. Boothbay Fund Management LLC bought a new position in Avalo Therapeutics during the 2nd quarter worth $56,000. Dimensional Fund Advisors LP bought a new stake in Avalo Therapeutics in the 3rd quarter valued at about $143,000. AlphaCentric Advisors LLC bought a new position in Avalo Therapeutics in the 1st quarter worth about $174,000. California State Teachers Retirement System bought a new position in Avalo Therapeutics in the 2nd quarter worth about $196,000. Finally, Jump Financial LLC bought a new stake in shares of Avalo Therapeutics during the fourth quarter valued at approximately $238,000. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.